

REACH - a non-regulatory announcement
AIM: FIPP
20 October 2025

Frontier IP Group plc
("Frontier IP" or the "Group")

Portfolio news - Amprologix raises £740,000 in pre-Series A funding round to accelerate development of novel antibiotics

Frontier IP, a specialist in commercialising intellectual property, today notes the following announcement from portfolio company Amprologix (or the "Company") that it has raised £740,000 to accelerate development of its novel antibiotics to combat antimicrobial-resistant diseases.

The money will be used to complete pre-clinical development of the Company's lead candidate, epidemycin NI01, in readiness for Phase I human clinical trials in 2026. Amprologix is also positioning itself for a Series A funding round.

Investors in the funding round include angel-investor network Plutus Investment Group LLP, another institution, and individuals. Plutus Investment Group's Venture Partner Dr Rita Dobmeyer is to join the Amprologix board as a Non-Executive Director and will support clinical development. Global full-service Contract Research Organisation InClin is supporting pre-clinical and clinical development work.

Epidemycin NI01 is being developed to tackle Methicillin-resistant *Staphylococcus aureus* (MRSA), a leading cause of healthcare-associated and community-acquired infections. Amprologix is also in the early stages of developing a novel antibiotic for prevention and treatment of *Clostridioides difficile* (*C. difficile*) infections.

Frontier IP Chief Executive Officer Neil Crabb said: *"The World Health Organisation has identified antimicrobial resistant diseases as one of the top 10 threats to human health globally. I am therefore excited by the potential for Amprologix's novel antibiotics in helping to fight this scourge. Research results to date have been highly encouraging, and I am delighted by the success of this funding round, which will play a vital role in taking epidemycin NI01 through to human clinical trials."*

Amprologix statement begins:

Amprologix raises £740,000 in pre-Series A funding round to accelerate development of novel antibiotics

[20 October 2025] Amprologix, a company pioneering new families of antibiotics, today announces that it has raised £740,000 through a pre-Series A investment round to accelerate development of its novel antibiotics to tackle antimicrobial-resistant diseases.

The funds will be used to complete pre-clinical development of its lead candidate epidemycin NI01 to support Phase I human clinical trials for therapy of wound infections. New research has shown that a daily dose of epidemycin NI01 is as effective at treating wound infections, including those caused by Methicillin-resistant *Staphylococcus aureus* (MRSA), as the current standard of care.

Antimicrobial resistance is one of the top 10 threats to human health globally, according to the World Health Organization (WHO). In a recent report, the WHO said there had been a sharp rise in infections resistant to antibiotics between 2018 and 2023, in some groups of pathogens. MRSA is one of the most common causes of hospital and community acquired bloodstream infections, according to the WHO and it is classed as a 'high-priority' antibiotic resistant pathogen.

Amprologix, a spinout company of the University of Plymouth, was founded to commercialise the pioneering research of Professor of Medical Microbiology Mathew Upton. It is also in the early stages of developing a novel antibiotic for *Clostridioides difficile* (*C. difficile*) infection. MRSA and *C. difficile* both cause infections that can be difficult to treat and new therapies are urgently needed.

The raised funds will enable the company to provide £300,000 of matched funding to deliver the £1 million TOBRADERM R&D project. Supported by Innovate UK's highly competitive Biomedical Catalyst programme, the project is aimed at advancing epidemycin NI01 through late pre-clinical testing for common skin and wound infections.

Investors include angel-investor network Plutus Investment Group LLP, another institution and individual angel investors. Plutus Investment Venture Partner Dr Rita Dobmeyer is to join the Amprologix board as a Non-Executive Director. She is an expert in strategic clinical development. Global full-service Contract Research Organisation InClin is to support pre-clinical and clinical development work.

Amprologix is also positioning itself for a Series A funding round with the intention of raising £5 million to support the

first human clinical trials of epidemycin NI01 in 2026, and the expansion of the portfolio of new drugs in development.

Mohammed Jamal, Chief Executive Officer and Chairman of Plutus Investment Group, said: *"Plutus are delighted to be working with Amprologix to help secure this important seed funding that will allow the company to achieve key preclinical milestones and we're looking forward to helping with a subsequent series-A round."*

Professor Mat Upton, Amprologix Chief Scientific Officer and Professor of Medical Microbiology at the University of Plymouth, said: *"I am extremely excited about the work that we will be able to carry out in the coming months with the recently secured investment. This will strengthen the case for development of epidemycin NI01 into a new therapy for skin infections that are a cause of pain and suffering for thousands of people in the UK every day."*

"We urgently need new therapies for these and other infections, some of which are life-threatening, and epidemycin has the potential to meet this need."

"Investment into this field is essential if we are going to make progress addressing the rise of drug-resistant infections, which threaten modern medical care. The support provided by our new investors is vital if we are to be successful in these efforts."

Amprologix Statement ends

ENQUIRIES

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

neil@frontierip.co.uk

Andrew Johnson, Communications and investor relations

M: 07464 546 025

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / Dan Dearden-Williams

ABOUT FRONTIER IP

Frontier IP unites science, finance and industry by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAQDLFFEBLEFBF